Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBT: 2016-2025

Historic EBT for Akebia Therapeutics (AKBA) over the last 9 years, with Sep 2025 value amounting to $1.2 million.

  • Akebia Therapeutics' EBT rose 105.76% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.3 million, marking a year-over-year increase of 66.76%. This contributed to the annual value of -$69.4 million for FY2024, which is 33.67% down from last year.
  • According to the latest figures from Q3 2025, Akebia Therapeutics' EBT is $1.2 million, which was up 367.61% from $247,000 recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' EBT peaked at $29.0 million during Q2 2022, and registered a low of -$84.3 million during Q2 2021.
  • Its 3-year average for EBT is -$10.3 million, with a median of -$11.2 million in 2023.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 134.44% in 2022, then tumbled by 3,814.01% in 2024.
  • Akebia Therapeutics' EBT (Quarterly) stood at -$70.4 million in 2021, then soared by 90.76% to -$6.5 million in 2022, then surged by 109.44% to $614,000 in 2023, then crashed by 3,814.01% to -$22.8 million in 2024, then spiked by 105.76% to $1.2 million in 2025.
  • Its EBT stands at $1.2 million for Q3 2025, versus $247,000 for Q2 2025 and $6.1 million for Q1 2025.